---
figid: PMC6512135__JAH3-8-e010961-g007
figtitle: Illustration of proposed effects of the phosphoinositide 3‐kinase (PI3K)
  pathway inhibition on the heart in the setting of anthracycline cancer therapy
organisms:
- Zea mays
- Triticum aestivum
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6512135
filename: JAH3-8-e010961-g007.jpg
figlink: /pmc/articles/PMC6512135/figure/jah34084-fig-0007/
number: F7
caption: Illustration of proposed effects of the phosphoinositide 3‐kinase (PI3K)
  pathway inhibition on the heart in the setting of anthracycline cancer therapy.
  PI3K pathway inhibition, a central pathway downstream of receptor tyrosine kinases
  (RTKs), such as HER2 (Human Epidermal Growth Factor Receptor 2), promotes biventricular
  remodeling with reduced left ventricular (LV) mass and right ventricular (RV) dilation
  and reduced ejection fraction (EF) in the setting of chemotherapy involving wasting
  syndrome (cachexia), MAPK (p38 mitogen‐activated protein kinase) activation, and
  oxidation‐reduction stress. LA indicates left atrium; MAPK, mitogen‐activated protein
  kinase; PA, pulmonary artery; RA, right atrium.
papertitle: PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct
  Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction.
reftext: Brent A. McLean, et al. J Am Heart Assoc. 2019 May 7;8(9):e010961.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8762473
figid_alias: PMC6512135__F7
figtype: Figure
redirect_from: /figures/PMC6512135__F7
ndex: e04fef2d-df1a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6512135__JAH3-8-e010961-g007.html
  '@type': Dataset
  description: Illustration of proposed effects of the phosphoinositide 3‐kinase (PI3K)
    pathway inhibition on the heart in the setting of anthracycline cancer therapy.
    PI3K pathway inhibition, a central pathway downstream of receptor tyrosine kinases
    (RTKs), such as HER2 (Human Epidermal Growth Factor Receptor 2), promotes biventricular
    remodeling with reduced left ventricular (LV) mass and right ventricular (RV)
    dilation and reduced ejection fraction (EF) in the setting of chemotherapy involving
    wasting syndrome (cachexia), MAPK (p38 mitogen‐activated protein kinase) activation,
    and oxidation‐reduction stress. LA indicates left atrium; MAPK, mitogen‐activated
    protein kinase; PA, pulmonary artery; RA, right atrium.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pik3r1
  - Mapk14
  - Crk
  - Grap2
  - Syp
  - Ahsa1
  - Erbb2
  - Apk
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - ERBB2
  - FBN1
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Pa
  - ra
  - rv
  - Tie
  - Ras85D
  - InR
  - MKP-4
  - p38b
  - rl
  - p38a
  - p38c
  - lic
  - Nurf-38
  - Ebp
  - Hrb87F
  - mas
  - myoblast-specific
  - ef
  - Nplp1
  - anthracyclines
  - cachexia
---
